Prostate cancer (Pca) is the most commonly diagnosed cancer affecting men in France. Before the age of 75 years old, 1 in 8 French men will have Pca. Androgen deprivation therapies (ADT) remain the standard of care. Such therapies induce significant bone loss. The bone-remodelling cycle depends on the androgen synthesis signalling pathways. Furthermore, age-specific hormonal decline plays a key role in the decrease in bone mass. As a result, the older the patients, the more likely they are to have osteoporosis if they are treated with hormone therapy. Their risk of osteoporotic fracture has an impact on their quality of life and their capacity of independent living. In recent years, newer hormone therapies (acetate abiraterone, enzalutamide, apalutamide and darolutamide) have proved efficient in metastatic castration-resistant Pca (mCRPC) patients as well as in hormone naïve patients, and actually in nonmetastatic diagnosis. The combination of these treatments with ADT highly inhibit androgen production pathways. They are prescribed to aged patients undergoing bone density loss after first-generation antiandrogen treatment. Specific recommendations for bone health management in Pca patients are currently lacking. To date, bone mineral density in patients treated with second-generation hormone therapy has never been assessed in a prospective study. This review aims at reviewing what is known about the impact of second-generation hormonotherapy on bone microenvironment.

中文翻译：

---

前列腺癌和骨微环境中的第二代激素疗法。

前列腺癌 (Pca) 是法国最常诊断出的影响男性的癌症。在 75 岁之前，每 8 名法国男性中就有 1 名患有 Pca。雄激素剥夺疗法 (ADT) 仍然是护理标准。这种疗法会引起显着的骨质流失。骨重塑周期取决于雄激素合成信号通路。此外，特定年龄的激素下降在骨量减少中起关键作用。因此，年龄越大的患者，如果接受激素治疗，他们患骨质疏松症的可能性就越大。他们患骨质疏松性骨折的风险会影响他们的生活质量和独立生活的能力。近年来，较新的激素疗法（醋酸阿比特龙、恩杂鲁胺、apalutamide 和 darolutamide) 已被证明对转移性去势抵抗性 Pca (mCRPC) 患者以及激素初治患者有效，实际上在非转移性诊断中也有效。这些治疗与 ADT 的组合高度抑制雄激素产生途径。它们适用于在第一代抗雄激素治疗后经历骨密度下降的老年患者。目前缺乏针对 Pca 患者骨骼健康管理的具体建议。迄今为止，从未在一项前瞻性研究中评估过接受第二代激素治疗的患者的骨矿物质密度。本综述旨在回顾关于第二代激素疗法对骨微环境影响的已知情况。这些治疗与 ADT 的组合高度抑制雄激素产生途径。它们适用于在第一代抗雄激素治疗后经历骨密度下降的老年患者。目前缺乏针对 Pca 患者骨骼健康管理的具体建议。迄今为止，从未在一项前瞻性研究中评估过接受第二代激素治疗的患者的骨矿物质密度。本综述旨在回顾关于第二代激素疗法对骨微环境影响的已知情况。这些治疗与 ADT 的组合高度抑制雄激素产生途径。它们适用于在第一代抗雄激素治疗后经历骨密度下降的老年患者。目前缺乏针对 Pca 患者骨骼健康管理的具体建议。迄今为止，从未在一项前瞻性研究中评估过接受第二代激素治疗的患者的骨矿物质密度。本综述旨在回顾关于第二代激素疗法对骨微环境影响的已知情况。从未在一项前瞻性研究中评估过接受第二代激素治疗的患者的骨矿物质密度。本综述旨在回顾关于第二代激素疗法对骨微环境影响的已知情况。从未在一项前瞻性研究中评估过接受第二代激素治疗的患者的骨矿物质密度。本综述旨在回顾关于第二代激素疗法对骨微环境影响的已知情况。